Navigation Links
ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
Date:8/19/2007

VaxGen's Recombinant Protective Antigen Anthrax Vaccine to be tested with

ImmuneRegen's Adjuvant

SCOTTSDALE, Ariz., Aug. 7 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced it has finalized a Material Transfer Agreement (MTA) with VaxGen Inc. (Pink Sheets: VXGN.PK). As part of the agreement, ImmuneRegen will receive the pharmaceutically active ingredient of VaxGen's anthrax vaccine candidate, recombinant Protective Antigen, or rPA, to be tested at one of ImmuneRegen's partnering labs. Commercial terms of the MTA were not disclosed.

VaxGen's rPA102 anthrax vaccine is composed of a purified rPA and an aluminum salt adjuvant routinely used in many vaccines. ImmuneRegen will be testing for adjuvant activity of ImmuneRegen's Viprovex(R) in combination with VaxGen's rPA.

"We are hoping to find that our compound, Viprovex, will demonstrate adjuvant activity in a rabbit model with the VaxGen vaccine," said Hal Siegel, Ph.D., Senior Director of Product Development and Regulatory Affairs, ImmuneRegen BioSciences, Inc. "From work we and others have already performed, we hope the adjuvant activity we recently reported in our studies with influenza vaccines in mice will be mirrored in testing of Viprovex with VaxGen's rPA antigen."

Initial studies in a well-established mouse model system have revealed that Viprovex can both prophylactically and therapeutically have positive effects in mice exposed to lethal doses of anthrax. Tests results indicated that animals exposed to lethal doses of anthrax spores were treated with different doses of Viprovex either before or after anthrax exposure and survival ranged from 20% to 70%.

The MTA with ImmuneRegen BioSciences is separate from VaxGen's effort to partner its recombinant anthrax vaccine program with another company for the purpose of carrying on the development and c
'/>"/>

SOURCE ImmuneRegen BioSciences

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
5. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
8. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
9. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
(Date:4/17/2014)... Canadians surveyed said they would participate in public health ... genetic conditions, only 80 per cent said they would ... their newborns, genomes.,Most newborns in North America have a ... of life in which a tiny amount of blood ... five to 54 conditions, depending on the state or ...
(Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
(Date:4/16/2014)... Texas (April 16, 2014) A team that includes scientists ... Health Science Center at San Antonio, Johns Hopkins University and ... helps a common fungus to infect the body. , The ... rashes and oral thrush, and is the most common fungal ...
(Date:4/15/2014)... Handling frozen fish caused nearly half of all ... the injuries on freezer-longliner vessels operating off the coast ... , Many of those injuries and others aboard the ... right interventions, and the research methods used in the ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... Diego – Obesity is back in the news with one ... Cancer. People who are obese carry an enhanced risk of ... California, San Diego have unearthed the link between obesity and ... the obese secrete a hormone called leptin, which induces growth ...
... proportions”, a study finding which says that hormone replacement therapy ... of heart disease. , The study published in ... replacement therapy or HRT, taken by women in their 50’s ... attacks and other such conditions. , This finding ...
... a possible herbal cure for urinary track// infection (UTI). ... Center found that the herb called forskalin or ... UTI as well as help antibiotics kill 90 percent of ... and Urologic Diseases Information Clearinghouse (NKUDIC) says urinary tract infections ...
... will soon start an integrated trauma care facility to ... //to patients on way to a hospital from an ... of Physicians of Indian Origin (AAPI), the emergency medical ... fully equipped ambulances within minutes of an accident., ...
... of developing colon cancer, the third most common form of ... body of obese people produce leptin - a hormone that ... a person has, the more leptin will be in their ... Surgery. ,A colon cancer patient suffers from cancerous ...
... US-based ImClone Systems and Bristol-Myers Squibb have announced that ... with platinum-based //chemotherapy have increased survival chances among cancer ... the head and neck (SCCHN). ,Worldwide SCCHN ... head and neck, and approximately two-thirds of all patients ...
Cached Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Ancient Indian Herb May Prove Cure For Recurrent UTI 2Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:A New Erbitux Combo Shows Promise in treatment 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... precise episcleral, intrascleral, and intraocular hemostasis ... Rf diathermy delivers targeted coagulation with ... Eraser instruments, forceps and cables. This ... a high level of Wet-Field safety ...
Medicine Products: